These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 2082833)
1. The effects of scleroderma sera on endothelial cell survival in vitro. Etoh T; Igarashi A; Iozumi K; Ishibashi Y; Takehara K Arch Dermatol Res; 1990; 282(8):516-9. PubMed ID: 2082833 [TBL] [Abstract][Full Text] [Related]
2. Cytotoxic effects of sera from patients with systemic scleroderma: comparison of three different in vitro methods. Majewski S; Błaszczyk M; Jabłonska S; Rudnicka L; Waşik M; Skiendzielewska A; Makieła B Rheumatol Int; 1990; 10(2):65-70. PubMed ID: 2349435 [TBL] [Abstract][Full Text] [Related]
5. Autoantibody to centromere (kinetochore) in scleroderma sera. Moroi Y; Peebles C; Fritzler MJ; Steigerwald J; Tan EM Proc Natl Acad Sci U S A; 1980 Mar; 77(3):1627-31. PubMed ID: 6966403 [TBL] [Abstract][Full Text] [Related]
6. Autoantibodies in childhood scleroderma. Bernstein RM; Pereira RS; Holden AJ; Black CM; Howard A; Ansell BM Ann Rheum Dis; 1985 Aug; 44(8):503-6. PubMed ID: 3875322 [TBL] [Abstract][Full Text] [Related]
7. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Ahmed SS; Tan FK; Arnett FC; Jin L; Geng YJ Arthritis Rheum; 2006 Jul; 54(7):2250-62. PubMed ID: 16802364 [TBL] [Abstract][Full Text] [Related]
8. Failure of sera from patients with scleroderma to exhibit cytotoxicity towards human umbilical vein endothelial cells. Summers GD; Weiss JB; Jayson MI Rheumatol Int; 1984; 5(1):9-13. PubMed ID: 6528183 [TBL] [Abstract][Full Text] [Related]
9. Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies? Benyamine A; Bertin D; Heim X; Granel B; Bardin N Eur J Intern Med; 2017 Oct; 44():e42-e44. PubMed ID: 28781194 [No Abstract] [Full Text] [Related]
10. Chromosome studies in scleroderma with consideration of anticentromere antibody status and assessment of possible in vitro clastogenic activity. Powell FC; Schroeter AL; Winkelmann RK; Dewald GW Acta Derm Venereol; 1986; 66(5):414-8. PubMed ID: 2431579 [TBL] [Abstract][Full Text] [Related]
12. [Anti-centromere antibody, biological marker of the CREST syndrome as distinct from scleroderma]. Rouquette-Gally AM; Stern MH; Prost AC; Abuaf N; Homberg JC; Combrisson A Presse Med; 1985 Jul 13-20; 14(28):1497-500. PubMed ID: 2931679 [TBL] [Abstract][Full Text] [Related]
13. [Is there a place of multiantigenes immunodot determination in systemic sclerosis patients without anti-centromeres or anti-Scl70 antibodies?]. Sautereau N; Gabsi A; Daumas A; Bardin N; Granel B Presse Med; 2015 May; 44(5):547-9. PubMed ID: 25813097 [No Abstract] [Full Text] [Related]
14. Cytotoxic activity of sera from scleroderma and other connective tissue diseases. Lack of cellular and disease specificity. Shanahan WR; Korn JH Arthritis Rheum; 1982 Dec; 25(12):1391-5. PubMed ID: 7150374 [TBL] [Abstract][Full Text] [Related]
19. Mitogenic activities for skin fibroblasts in the sera from untreated scleroderma patients at the early stage. Igarashi A; Takehara K; Soma Y; Kikuchi K; Ishibashi Y Arch Dermatol Res; 1989; 281(6):383-6. PubMed ID: 2596866 [TBL] [Abstract][Full Text] [Related]
20. [Significance of anti-centromere antibodies. Clinical value]. Meyer O; Haim T; Ryckewaert A Rev Rhum Mal Osteoartic; 1983 Apr; 50(4):261-6. PubMed ID: 6348931 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]